Selpercatinib (Retevmo, Loxo Oncology) is FDA-approved to treat 3 types of tumors—metastatic RET fusion-positive non-small cell lung cancer, advanced medullary thyroid cancer (MTC) or MTC that has spread, and advanced RET fusion-positive thyroid cancer.
Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.
Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the immune system to detect and fight tumor cells.
Fentanyl citrate (Actiq) is an opioid agonist indicated for the management of breakthrough pain in cancer patients.
The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.
As best practices are established throughout the specialty pharmacy’s entire network, better patient outcomes become possible.
Expert notes that any unease around the use of radiopharmaceuticals is just due to a lack of familiarity with the field.
Training pharmacy technicians to evaluate tasks such as appropriate site of care and plan benefits can reduce the workload for the pharmacist.
Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.
The treatment also significantly reduces the risk of progression or death and prolonged median PFS compared with fulvestrant in all individuals without prior chemotherapy, the analysis shows.
Although it has clear benefits when monitoring and managing cancer, Feinberg said more widespread use of circulating tumor DNA will take time.
Investigators report that the 2 individuals receiving the 120-mg dosage had 3 probable immune-related adverse events, which provides supportive evidence of immune activation.
Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.
In an analysis of data from 2 patient cohorts included in the phase 2 BYLieve study, investigators found that the data may indicate an increased dependence on the mutant PI3K-α.
Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.
Blinded independent central review analysis also adds confidence to the findings.
JZP458, a recombinant Erwinia-derived ASNase from a Pseudomonas fluorescens expression platform, was previously approved by the FDA for patients with ALL/LBL who had developed hypersensitivity to Escherichia coli (E. coli)–derived ASNase.
Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response.
Investigators found that individuals receiving selinexor had a median PFS of 5.7 months compared to 3.8 months for those given the placebo, with a stratification adjusted hazard ratio of 0.70.
The ability to measure GFR would be a significant advancement for clinicians in the United States.
Scot Ebbinghaus, MD, vice president of oncology clinical research at Merck, discussed the growing body of research surrounding pembrolizumab (Keytruda) and what it is currently being investigated for.
Additionally, the 2-time dependent variables, dose reduction, and relative dose intensity 2 (RDI2) were included in the respective model as covariates to explore the connection to overall survival.
Overall, the investigators observed that the CR, undetectable minimal residual disease rates, progression free survival, and overall survival amomg the patients enrolled in the trial were favorable.
Ginna Laport, MD, discussed the growing body of research surrounding venetoclax.
In a collaboration using a neutral zone, organizations do not have access to each other’s data, but will instead have access to insights gathered by pooling their data together with other organizations for analysis by artificial intelligence technology.
Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.
All individuals who received second-line chemotherapy regimens met the PFS2 endpoint and all but 1 individual had died at time of data cutoff, according to a presentation at 2022 ASCO Annual Meeting.
Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.
Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.
Biomarker positive patients were randomized to maintenance rucaparib 600 mg or matched placebo within 10 weeks of completing PBC until disease progression.
